Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

NMT (N-Myristoyltransferase)

  • Umashankar Das
  • Joel Howlett
  • Sujeet Kumar
  • Sreejit Parameswaran
  • Anil Sharma
  • Jonathan R. Dimmock
  • Rajendra K. Sharma
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_538

Synonyms

Historical Background

Lipid modification is one of the most common posttranslational modifications in eukaryotic cells that take place either at or near the amino terminus or the carboxy terminus of the proteins (Resh 2013). This process is sequence specific and classified as myristoylation, palmitoylation, prenylation, and glycosylphosphatidylinositol according to the identity of the attached lipid. The structural changes resulting from these modifications have effects on the stability, cellular location, and biological activity of the proteins (Resh 2013). These processes are becoming increasingly important for the study of cancer, as several key oncoproteins require this type of “posttranslational maturation” for their biological activity and for their ability to transform cells. Among these lipid modifications, protein myristoylation is known to be very important which refers to the covalent...

This is a preview of subscription content, log in to check access.

References

  1. Clegg RA, Gordge PC, Miller WR. Expression of enzymes of covalent protein modification during regulated and dysregulated proliferation of mammary epithelial cells: PKA, PKC and NMT. Adv Enzym Regul. 1999;39:175–203.CrossRefGoogle Scholar
  2. Das U, Kumar S, Dimmock JR, Sharma RK. Inhibition of protein N-myristoylation: a therapeutic protocol in developing anticancer agents. Curr Cancer Drug Targets. 2012;12:667–92.CrossRefPubMedGoogle Scholar
  3. Ducker CE, Upson JJ, French KJ, Smith CD. Two N-myristoyltransferase isozymes play unique roles in protein myristoylation, proliferation, and apoptosis. Mol Cancer Res. 2005;3:463–76.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Giang DK, Cravatt BF. A second mammalian N-myristoyltransferase. J Biol Chem. 1998;273:6595–8.CrossRefPubMedGoogle Scholar
  5. King MJ, Sharma RK. Demonstration of multiple forms of bovine brain myristoyl CoA:protein N-myristoyl transferase. Mol Cell Biochem. 1992;113:77–81.CrossRefPubMedGoogle Scholar
  6. Kumar S, Sharma RK. N-terminal region of the catalytic domain of human N-myristoyltransferase 1 acts as an inhibitory module. PLoS One. 2015;10:e0127661.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Lu Y, Selvakumar P, Ali K, Shrivastav A, Bajaj G, Resch L, Griebel R, Fourney D, Meguro K, Sharma RK. Expression of N-myristoyltransferase in human brain tumors. Neurochem Res. 2005;30:9–13.CrossRefPubMedGoogle Scholar
  8. Magnuson BA, Raju RV, Moyana TN, Sharma RK. Increased N-myristoyltransferase activity observed in rat and human colonic tumors. J Natl Cancer Inst. 1995;87:1630–5.CrossRefPubMedGoogle Scholar
  9. Rajala RV, Datla RS, Moyana TN, Kakkar R, Carlsen SA, Sharma RK. N-myristoyltransferase. Mol Cell Biochem. 2000a;204:135–55.CrossRefPubMedGoogle Scholar
  10. Rajala RV, Kakkar R, Kanthan R, Radhi JM, Wang X, Wang R, Datla RS, Sharma RK. Altered expression and localization of N-myristoyltransferase in experimentally induced rat model of ischemia-reperfusion. J Cell Biochem. 2002;86:509–19.CrossRefPubMedGoogle Scholar
  11. Rajala RV, Radhi JM, Kakkar R, Datla RS, Sharma RK. Increased expression of N-myristoyltransferase in gallbladder carcinomas. Cancer. 2000b;88:1992–9.CrossRefPubMedGoogle Scholar
  12. Raju RV, Moyana TN, Sharma RK. N-Myristoyltransferase overexpression in human colorectal adenocarcinomas. Exp Cell Res. 1997;235:145–54.CrossRefPubMedGoogle Scholar
  13. Resh MD. Covalent lipid modifications of proteins. Curr Biol. 2013;23:R431–5.PubMedPubMedCentralCrossRefGoogle Scholar
  14. Resh MD. Targeting protein lipidation in disease. Trends Mol Med. 2012;18:206–14.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Selvakumar P, Lakshmikuttyamma A, Shrivastav A, Das SB, Dimmock JR, Sharma RK. Potential role of N-myristoyltransferase in cancer. Prog Lipid Res. 2007;46:1–36.CrossRefPubMedGoogle Scholar
  16. Selvakumar P, Smith-Windsor E, Bonham K, Sharma RK. N-myristoyltransferase 2 expression in human colon cancer: cross-talk between the calpain and caspase system. FEBS Lett. 2006;580:2021–6.CrossRefPubMedGoogle Scholar
  17. Shoji S, Kurosawa T, Inoue H, Funakoshi T, Kubota Y. Human cellular src gene product: identification of the myristoylated pp60c-src and blockage of its myristoyl acylation with N-fatty acyl compounds resulted in the suppression of colony formation. Biochem Biophys Res Commun. 1990;173:894–901.CrossRefPubMedGoogle Scholar
  18. Shrivastav A, Sharma AR, Bajaj G, Charavaryamath C, Ezzat W, Spafford P, Gore-Hickman R, Singh B, Copete MA, Sharma RK. Elevated N-myristoyltransferase activity and expression in oral squamous cell carcinoma. Oncol Rep. 2007a;18:93–7.PubMedGoogle Scholar
  19. Shrivastav A, Varma S, Saxena A, DeCoteau J, Sharma RK. N-myristoyltransferase: a potential novel diagnostic marker for colon cancer. J Transl Med. 2007b;5:58.PubMedPubMedCentralCrossRefGoogle Scholar
  20. Shrivastav A, Varma S, Senger A, Khandelwal RL, Carlsen S, Sharma RK. Overexpression of Akt/PKB modulates N-myristoyltransferase activity in cancer cells. J Pathol. 2009;218:391–8.CrossRefPubMedGoogle Scholar
  21. Thinon E, Morales-Sanfrutos J, Mann DJ, Tat EW. N-myristoyltransferase inhibition induces ER-stress, cell cycle arrest, and apoptosis in cancer cells. ACS Chem Biol. 2016. doi:10.1021/acschembio. 6b00371.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Umashankar Das
    • 1
  • Joel Howlett
    • 2
  • Sujeet Kumar
    • 2
  • Sreejit Parameswaran
    • 2
  • Anil Sharma
    • 3
  • Jonathan R. Dimmock
    • 1
  • Rajendra K. Sharma
    • 2
    • 4
  1. 1.Drug Discovery and Development Research Group, College of Pharmacy and NutritionUniversity of SaskatchewanSaskatoonCanada
  2. 2.Department of Pathology and Laboratory Medicine, College of MedicineUniversity of SaskatchewanSaskatoonCanada
  3. 3.ENT clinicSaskatoonCanada
  4. 4.Cancer Research Unit, Saskatchewan Cancer AgencySaskatoonCanada